Selected article for: "acute sars cov respiratory syndrome coronavirus and additionally viral"

Author: McDade, Thomas W.; Demonbreun, Alexis R.; Sancilio, Amelia; Mustanski, Brian; D’Aquila, Richard T.; McNally, Elizabeth M.
Title: Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
  • Cord-id: elycje9y
  • Document date: 2021_8_30
  • ID: elycje9y
    Snippet: Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccin
    Document: Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.

    Search related documents:
    Co phrase search for related documents
    Co phrase search for related documents, hyperlinks ordered by date